{"id":11319,"date":"2026-02-18T05:54:09","date_gmt":"2026-02-18T05:54:09","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/11319\/"},"modified":"2026-02-18T05:54:09","modified_gmt":"2026-02-18T05:54:09","slug":"novartis-advances-kidney-drug-and-radioligand-pipeline-with-key-milestones","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/11319\/","title":{"rendered":"Novartis Advances Kidney Drug And Radioligand Pipeline With Key Milestones"},"content":{"rendered":"\n

Track your investments for FREE<\/a> with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.<\/p>\n

Novartis (SWX:NOVN) reports positive final Phase III results for Vanrafia in patients with IgA nephropathy.<\/p>\n

The company also signs a long term supply agreement with Niowave for Actinium-225 to support its radioligand therapy pipeline.<\/p>\n

For you as an investor, this update touches two different parts of Novartis\u2019s business. Vanrafia targets IgA nephropathy, a serious kidney disease where treatment choices remain limited, which fits with the company\u2019s broader focus on specialty and chronic conditions. At the same time, the Actinium-225 supply agreement relates to its work in radioligand therapies, an area within precision cancer medicine.<\/p>\n

These moves indicate that SWX:NOVN is working on both deepening its late stage pipeline and securing key inputs needed for potential future products. As these programs proceed through regulatory and commercial steps, investors watching Novartis may pay close attention to clinical follow up, manufacturing capacity and partnership activity related to radioligand therapies.<\/p>\n

Stay updated on the most important news stories for Novartis<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Novartis.<\/p>\n

\"SWX:NOVN<\/a> SWX:NOVN Earnings & Revenue Growth as at Feb 2026 <\/p>\n

We’ve flagged 1 risk for Novartis. See which could impact your investment.<\/a><\/p>\n

The Vanrafia Phase III readout points to a potential new option in IgA nephropathy, a disease area with limited treatments and a long course of care. While the primary eGFR result at Week 136 came with a p value close to the usual statistical threshold, the clinically meaningful differences reported at Week 132 and in patients also using SGLT2 inhibitors suggest Novartis is targeting a segment where physicians and payers look closely at kidney function preservation. If approved, Vanrafia would add another kidney and autoimmune asset alongside peers such as AstraZeneca and Roche that are also active in renal and immunology therapies. Separately, locking in long term Actinium-225 supply tackles one of the key bottlenecks in radioligand therapies, where companies like Eli Lilly and Bayer are also investing. For you, these moves together highlight Novartis\u2019 focus on late stage programs in specialty areas and on securing hard to source materials for its cancer pipeline. This can influence how resilient future product revenues may be.<\/p>\n

The Vanrafia data and Actinium-225 agreement are aligned with the narrative that emphasizes advanced therapies and a strong late stage pipeline as drivers of future revenue and margin resilience.<\/p>\n

Clinical nuances around Vanrafia\u2019s eGFR results, including p values close to conventional cutoffs and a key safety warning on birth defects, could temper the contribution assumed for new renal and autoimmune assets in the narrative.<\/p>\n

The specific long term isotope supply for radioligand therapies, and the potential breadth of indications it might support, are not fully captured in the broad references to US manufacturing build out and advanced therapies in the existing narrative.<\/p>\n

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Novartis<\/a> to help decide what it’s worth to you.<\/p>\n

\u26a0\ufe0f Vanrafia carries a serious safety warning related to birth defects, so regulators, prescribers and payers may restrict use, which could limit uptake compared with other kidney or autoimmune therapies.<\/p>\n

\u26a0\ufe0f Radioligand therapies rely on complex manufacturing and isotope logistics, so any disruption in Actinium-225 production or regulatory constraints around radioisotopes could affect Novartis\u2019 cancer treatment roll out.<\/p>\n

\ud83c\udf81 Positive Phase III data in IgA nephropathy adds another late stage asset in a condition with high unmet need, which can support the company\u2019s positioning in kidney and autoimmune diseases.<\/p>\n

\ud83c\udf81 Securing scalable Actinium-225 supply early may give Novartis an edge over competitors such as Eli Lilly and Bayer that are also expanding radiopharmaceutical portfolios in an area where global isotope supply remains tight.<\/p>\n

From here, you may want to track regulatory filings and guidance for Vanrafia, especially how regulators frame its benefit risk profile and any restrictions around pregnancy. For radioligand therapies, key markers will be the pace of clinical readouts, manufacturing capacity build out and any disclosures on how much of the pipeline will rely on Actinium-225 compared with other isotopes. It can also be useful to compare Novartis\u2019 progress and disclosures with peers working on kidney disease and targeted cancer therapies to gauge how competitive its pipeline looks over time.<\/p>\n

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Novartis, head to the community page for Novartis<\/a> to never miss an update on the top community narratives.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include NOVN.SW<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…\n","protected":false},"author":2,"featured_media":134,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[8512,6668,206,8514,637,8513],"class_list":{"0":"post-11319","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-iga-nephropathy","9":"tag-kidney-disease","10":"tag-novartis","11":"tag-radioligand-therapy","12":"tag-supply-agreement","13":"tag-therapies"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/11319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=11319"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/11319\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/134"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=11319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=11319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=11319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}